# High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

> **NCT06971406** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qiming Wang** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Mutation
- Leptomeningeal Metastases
- Targeted Therapy

## Interventions

- **DRUG:** Combination therapy prospective cohort

## Key facts

- **NCT ID:** NCT06971406
- **Lead sponsor:** Qiming Wang
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06971406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06971406, "High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06971406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*